Inflammation Creates New Therapeutic Vulnerabilities in Cancer: Nature Genetics | June 2026

• Cancer cells constantly adapt to inflammatory stress generated by the immune system, particularly during immune checkpoint inhibitor therapy.
• This study explored whether inflammatory cytokines such as interferon-γ (IFNγ), interferon-β, and TNF create new weaknesses that can be therapeutically exploited.
• Using genome-wide CRISPR screening across multiple cancer models, investigators identified previously unrecognized cancer dependencies that emerge specifically under inflammatory conditions.
• Two major targets emerged:

GPI transamidase complex

FITM2 (Fat Storage-Inducing Transmembrane Protein 2)

• These genes were not simply general survival genes; they became particularly important when tumour cells were exposed to interferon signaling.
• Deletion of GPI transamidase components or FITM2 significantly enhanced tumour responses to immune checkpoint blockade in preclinical models.
• Mechanistic studies revealed that FITM2 loss makes tumour cells highly susceptible to interferon-driven stress responses.
• Inflammatory cytokines triggered excessive endoplasmic reticulum stress and oxidative stress in FITM2-deficient cancer cells.
• This ultimately resulted in a distinctive form of programmed cell death resembling paraptosis, which differs from classical apoptosis.
• The findings suggest that immune activation does not only attack cancer directly but may also expose previously hidden metabolic and stress-related vulnerabilities.
• This represents an important conceptual advance in immuno-oncology: inflammatory signaling may create new drug targets that only become relevant during active antitumour immune responses.
• Combining immune checkpoint inhibitors with therapies targeting inflammation-induced dependencies could potentially improve response rates and overcome resistance.
• The study also highlights the growing role of functional genomics and CRISPR screening in identifying context-specific cancer vulnerabilities.
• Although the work remains preclinical, it provides a framework for developing combination strategies that exploit tumour adaptation to immune pressure.
• Future therapeutic development may focus on pharmacologic inhibition of FITM2-related pathways or GPI transamidase function alongside immunotherapy.

Bottom line: Antitumour inflammatory cytokines do more than activate immune responses—they create new tumour-specific dependencies. Targeting FITM2 and GPI transamidase–related pathways may enhance the effectiveness of immune checkpoint blockade and open a new avenue for precision immuno-oncology.